OncoMatch/Clinical Trials/NCT06088030

Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer

Is NCT06088030 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Arsenic trioxide for pediatric cancer.

Phase 2RecruitingYang LiNCT06088030Data as of May 2026

Treatment: Arsenic trioxide — This prospective, single-arm, multi-center clinical trial aims to explore and evaluate the efficacy and safety of arsenic trioxide combined with chemotherapy for pediatric cancer with p53 mutation.

Check if I qualify

Extracted eligibility criteria

Biomarker criteria

Required: TP53 mutation

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify